Figure 1.
Percentage of seroconversion for BALB/c mice immunized in early life using either HBsAg with adjuvant(s) or an HBsAg-expressing DNA vaccine. HBsAg (1 μg) was combined with either 25 μg Al3+ (open bars), 10 μg CpG ODN (striped bars), or both alum and CpG ODN (shaded bars). The DNA vaccine (10 μg) encoded HBsAg under the control of a cytomegalovirus promoter (pCMV-S) (solid bars). Mice were immunized at <1, 3, 7, or 14 days after birth, and plasma taken at 12 weeks postimmunization was assayed for anti-HBs by endpoint-dilution ELISA assay. The fraction of mice exhibiting an anti-HBs endpoint-dilution titer >100 for any treatment is listed above the bar for that treatment.